Investor Presentation FY23 Growth Acceleration

Operating expenses / staff numbers Higher expenses reflect planned investment in R&D, commercialisation and organisational capability Employee benefits expense $'000s Cost of goods sold FY22 FY21 Change $ Change % · 1,485 668 816 122% Previously signaled investment in headcount to support growth including 12 via acquisition Research & Development Sales & Marketing 4,592 2,783 1,809 65% • 1,971 695 1,276 184% General and Administration Total employee benefits 2,783 2,197 586 27% • 10,830 6,343 4,487 71% Staff nos. (FTE) as at 31 March 2022 FY22 FY21 Change $ Change % Cost of goods sold 17 9 8 86% Research & Development 41 27 14 51% Sales & Marketing 17 12 5 39% General and Administration 15 9 6 70% Total staff nos. (FTE) 89 57 32 57% Other expenses $'000s FY22 FY21 Change $ Change % Cost of goods sold 459 377 83 22% Research & Development 301 341 (40) -12% Sales & Marketing 559 346 213 62% General and Administration 2,274 800 1,475 184% Total 3,594 1,864 1,730 93% TradeWindow • R&D up $1.8m to support current and future growth (employee numbers from 27 to 41) No R&D cost capitalised to balance sheet Increased sales capability in New Zealand and Australia General and administration up-building organisational capability (e.g. HR, Finance) to support listed environment and growth opportunities Other expenses included one-off listing costs ($0.5m) and related ongoing costs increases ($0.6m) (insurance, audit, professional) Investor presentation 27

View entire presentation